Gastric & Breast Cancer
DOI: 10.2122/gbc.2004.0030
Improving
Decision for Cancer Prevention of Women with BRCA
Mutations
Niki J. Agnantis, MD, PhD, Evangelos
Paraskevaidis, MD,Evangelos Briasoulis,MD, Ioannis
Arambatzis, MD,
and Dimitrios Roukos, MD.
From
the Departments of Pathology (NJA), Gynecology
& Obstetrics (EP),Medical Oncology (EB) and
Surgery (DHR), at the Ioannina University School
of Medicine, GR –45110, Ioannina, Greece.
Correspondence to: Dimitrios H. Roukos, MD, Ioannina
University School of Medicine, GR –45110, Ioannina,
Greece, or email:
droukos@cc.uoi.gr
A
decade after the discovery of BRCA1
and BRCA2 genes, enormous research
advances have been made. A high breast,
ovarian cancer risk has been established
pressing for a prevention decision.
But as surgical and nonsurgical options
abound, increases parallel the uncertainty
about a right choice.
On one hand, prophylactic surgery
-bilateral mastectomy (BM), bilateral
salpingo-oophorectomy (BSO) and resection
of both breasts and ovaries, dramatically
reduces cancer risk at the organ(s)
targeted by the BRCA mutated genes
but at the cost of all disadvantages
of a surgical approach. On the other,
surveillance strategies providing
an excellent quality of life (QoL)
represent women’s preferences. Lifelong
preservation –due incomplete penetrance
or modifying the genetic risk (tamoxifen)-
or surgical resection only when early-stage
cancer becomes clinically evident,
is an ideal goal. But is research
sufficient for integration into clinical
practice without risks?
Wide variation in risk estimates,
diverse impacts of surgical and nonsurgical
preventive measures on survival and
QoL, as well as lacking of randomized
controlled trial, make a right decision
too complicated and extremely challenging.
As new data have become available,
what is the preventive intervention
that provides the best risk-benefit
ratio in clinical practice regarding
risk reduction, survival and quality
of life?
|
|
|
|
|
|
Online
ISSN : 1109 - 7647
Print ISSN : 1109 - 7655 |
|
last
update: 3 February 2004 |
|
|
|